Influenza infection is a worldwide health and financial burden posing a significant risk to the immune-compromised, obese, diabetic, elderly, and pediatric populations. We identified increases in metabolism in the lungs of immune-compromised patients infected with respiratory pathogens. Using quantitative mass spectrometry we found metabolic changes occurring after influenza infection in primary human respiratory cells, and defined the molecular underpinnings of these changes. We developed a metabolic drug screen and high-throughput titer on human respiratory cells to identify potential drugs targets. Several targets were identified that had efficacy in vitro and/or in vivo. There remains a need for methods of treating viral infections (i.e., influenza viral infection) via alternative methods that are less likely to generate viral escape. Here we propose that metabolic pathways are an outstanding host target that the virus cannot easily escape from, that viral infection results in metabolic reprogramming of host cells, and thus that metabolic targets are ideal for therapeutic intervention.
Researchers at St. Jude have invented a way to treat viral infections using known drugs or combinations of drugs, based on specific structures, in appropriate amounts, with pharmaceutical salts, and/or antiviral agent, and/or an agent to weaken the immune system; and a carrier. They have also invented kits comprising the same.
Influenza, drug combination, viral , anti-viral, respiratory, immune
Granted Patents or Published Applications
St. Jude has applied for a patent and a publication has been submitted.
Related Scientific References
We are seeking a partner interested in licensing and developing this technology.
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.